Goal-directed Hemodynamic Management and Kidney Injury After Radical Nephrectomy or Nephroureterectomy
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Dec 7, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific type of medical management during surgery can help protect the kidneys from injury. The surgeries involved are called radical nephrectomy and nephroureterectomy, which are performed to treat certain types of kidney and urinary tract cancers. Unfortunately, many patients experience acute kidney injury after these surgeries, which can lead to long-term kidney problems. The researchers believe that a tailored approach to managing blood flow and hydration during surgery may lower the risk of kidney injury and improve overall kidney health in the long run.
To participate in this study, you need to be at least 18 years old and scheduled for one of the surgeries mentioned. However, if you have severe chronic kidney disease, uncontrolled high blood pressure, certain heart conditions, or other serious health issues, you may not be eligible. If you join the study, you can expect careful monitoring and support during your surgery to help maintain healthy kidney function. This trial aims to provide valuable insights that could improve care for future patients undergoing these surgeries.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Age of 18 years or older;
- • 2. Scheduled to undergo unilateral radical nephrectomy for renal cancer or unilateral radical nephroureterectomy for upper tract urothelial carcinoma.
- • Exclusion criteria
- • 1. Diagnosed with chronic kidney disease stage 4 or stage 5 (GFR\<30 ml/min/1.73m2) before surgery;
- • 2. Uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg);
- • 3. Combined with cardiovascular diseases with Revised Cardiac Risk Index (RCRI) \>1 or metabolic equivalents (METs) \<4;
- • 4. Unable to communicate due to severe dementia, language barrier, or end-stage disease before surgery;
- • 5. Other conditions that are considered unsuitable for inclusion (specific reasons should be indicated).
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials